The union representing workers at Samsung Biologics (207940.KS), the world's largest contract biopharmaceutical manufacturer, voted on Sunday to break away from the Samsung Group United Union, a group-wide labor coalition of Samsung affiliates formed in February 2024. The move turns Samsung Biologics' union into an independent, company-level bargaining unit just as a six-month wage dispute — one that has already triggered the firm's first-ever strike — grinds toward another round of talks.
What changed, and what didn't
This is a change in who represents the workers, not a fresh walkout. Of 4,005 members eligible to vote, 2,479 cast ballots over the five-day poll that ran June 24-28, and 2,392 — 96.5% of those voting — backed leaving the coalition, according to the Samsung Biologics union as reported by Chosun Biz and the Korea Times. Passage required a majority of all members to vote and two-thirds of voters to approve. A union official told Chosun Biz the exit would be complete "within days" once administrative steps finish.
The production risk the headline points to
For a plant complex that anchors a large slice of global biologics supply, the central financial risk is production disruption. Samsung Biologics has estimated losses tied to the labor action at about ₩150 billion ($109 million), revised down from an earlier worst-case figure of as much as ₩640 billion ($467 million) under a full-shutdown scenario, the Korea Herald reported. Set against the company's record 2025 consolidated revenue of ₩4.56 trillion ($3.3 billion) — up roughly 30% on the year, with operating profit of about ₩2.07 trillion ($1.5 billion), the company's first year above the ₩2 trillion operating-profit mark — the ₩150 billion estimate equals roughly 3% of annual sales (LineVest calculation from the Korea Herald loss figure and the company's reported FY2025 results). The capacity at issue is the world's largest contract biomanufacturing footprint, which Samsung Biologics puts at 784,000 liters across its five Songdo plants near Incheon following the April 2025 start-up of its 180,000-liter Plant 5.
Why the union is going it alone
The decision follows a dispute that hardened, then lost momentum. The union staged a roughly 60-person partial strike in late April, escalated to a five-day full strike from May 1-5 that drew about 2,800 workers — more than half the workforce and the company's first stoppage since its 2011 founding — then shifted to a "work-to-rule" campaign of refusing overtime and weekend shifts while adhering to good manufacturing practice standards, per the Korea Herald. Some members in the work-to-rule action face pay cuts of up to about ₩1.5 million ($1,100), Chosun Biz reported, and internal cohesion has frayed: a union briefing held June 16-18 drew about 200 attendees, down from the more than 700 who turned out before the April strike, according to Chosun Biz. The union said in the ballot materials it judged a standalone company union better able to reflect members' demands "directly and quickly."
A second crack in the coalition
According to a union official quoted by Chosun Biz, Samsung Biologics is only the second affiliate to leave the Samsung Group United Union, after the union at Samsung Electro-Mechanics (009150.KS), the group's electronic-components maker; LineVest could not independently confirm the sequence. The coalition — which launched in February 2024 with roughly 15,800 members across the device-experience (consumer) division of Samsung Electronics (005930.KS), the group's flagship chip and smartphone maker, plus panel unit Samsung Display, non-life insurer Samsung Fire & Marine and Samsung Biologics itself, and later grew above 70,000 as Samsung Electronics workers joined en masse — has been shedding members since a recent Samsung Electronics labor settlement stirred discontent over differentiated bonus payouts, Chosun Biz reported. The exit of a founding member compounds that strain.
The gap that still has to close
The two sides remain far apart. The union is seeking a base-pay increase of about 14%, a ₩30 million ($21,900) per-person incentive, a bonus pool set at 20% of operating profit, removal of the bonus cap and an allocation of treasury shares; management has offered a 6.2% raise and a lump sum of about ₩6 million ($4,380), per Chosun Biz and Korea Herald reporting. The union has argued the company applied a group-level wage guideline despite its own record earnings.
What to watch next
The next read comes quickly. Samsung Biologics and the union are scheduled to return to the table on July 1-2, the union told Chosun Biz, describing the resumed talks as still at a "probing" stage. Whether the newly independent union uses its company-level mandate to harden demands or to strike a faster deal — and whether the work-to-rule campaign eases or extends — will determine whether the ₩150 billion loss estimate holds or grows. The clearest confirmation either way will land with the outcome of the July 1-2 sessions and the company's next quarterly results.
This article is for informational purposes only and does not constitute investment advice. Figures are sourced as cited; currency conversions use an approximate rate of 1 USD = 1,370 KRW.
